Antitumor effects of murine bone marrow-derived dendritic cells infected with xenogeneic livin α recombinant adenoviral vectors against Lewis lung carcinoma

Lung Cancer

Volumn 68, Issue 3, 2010, Pages 338-345

  Xie, Junping ^a,b   Xiong, Liang ^a,b   Tao, Xiaonan ^a,b   Li, Xiao ^a,b   Su, Yuan ^a,b   Hou, Xiaohua ^a   Shi, Huanzhong ^a,b  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^b BEIJING HOSPITAL   (China)

Author keywords

Adenoviral vector; Cytotoxic T lymphocyte (CTL); Dendritic cells; Lewis lung carcinoma; Livin ; Tumor vaccine

Indexed keywords

ADENOVIRUS VECTOR; LIVIN; LIVIN ALPHA; UNCLASSIFIED DRUG; BIRC7 PROTEIN, HUMAN; CANCER VACCINE; INHIBITOR OF APOPTOSIS PROTEIN; SIGNAL TRANSDUCING ADAPTOR PROTEIN; TUMOR PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; FEMALE; GENETIC TRANSFECTION; LEWIS CARCINOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR IMMUNITY; ADENOVIRIDAE; ANIMAL; BONE MARROW; C57BL MOUSE; CANCER TRANSPLANTATION; CARCINOMA, LEWIS LUNG; CYTOTOXICITY; GENE VECTOR; GENETIC TRANSDUCTION; GENETICS; HUMAN; IMMUNOLOGY; METABOLISM; MOLECULAR CLONING; PATHOLOGY; TRANSGENE; VIROLOGY;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ADENOVIRIDAE; ANIMALS; BONE MARROW; CANCER VACCINES; CARCINOMA, LEWIS LUNG; CLONING, MOLECULAR; CYTOTOXICITY, IMMUNOLOGIC; DENDRITIC CELLS; FEMALE; GENETIC VECTORS; HUMANS; INHIBITOR OF APOPTOSIS PROTEINS; MICE; MICE, INBRED C57BL; NEOPLASM PROTEINS; NEOPLASM TRANSPLANTATION; T-LYMPHOCYTES, CYTOTOXIC; TRANSDUCTION, GENETIC; TRANSGENES;

EID: 77952553028     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lungcan.2009.07.007     Document Type: Article

References (39)

1. Moscatello D.K., Ramirez G., Wong A.J. A naturally occurring mutant epidermal growth factor receptor as a target for peptide vaccine immunotherapy of tumors. Cancer Res 1997, 57:1419-1424.
2. Heimberger A.B., Crotty L.E., Archer G.E., Hess K.R., Wikstrand C.J., Friedman A.H., et al. Epidermal growth factor receptor VIII peptide vaccination is efficacious against established intracerebral tumors. Clin Cancer Res 2003, 9:4247-4254.
3. Ciesielski M.J., Kazim L., Barth R.F., Fenstermaker R.A. Cellular antitumor immune response to a branched lysine multiple antigenic peptide containing epitopes of a common tumor-specific antigen in a rat glioma model. Cancer Immunol Immunother 2005, 54:107-119.
4. Kasof G.M., Gomes B.C. Livin, a novel inhibitor of apoptosis protein family member. J Biol Chem 2001, 276:3238-3246.
5. Liu B., Han M., Wen J.K., Wang L. Livin/ML-IAP as a new target for cancer treatment. Cancer Lett 2007, 250:168-176.
6. Tanabe H., Yagihashi A., Tsuji N., Shijubo Y., Abe S., Watanabe N. Expression of survivin mRNA and livin mRNA in non-small-cell lung cancer. Lung Cancer 2004, 46:299-304.
7. Yagihashi A., Asanuma K., Kobayashi D., Tsuji N., Shijubo Y., Abe S., et al. Detection of autoantibodies to livin and survivin in Sera from lung cancer patients. Lung Cancer 2005, 48:217-221.
8. Overwijk W.W., Tsung A., Irvine K.R., Parkhurst M.R., Goletz T.J., Tsung K., et al. gp100/pmel 17 is a murine tumor rejection antigen: induction of " self" -reactive tumoricidal T cells using high-affinity altered peptide ligand. J Exp Med 1998, 188:277-286.
9. Nyberg-Hoffman C., Shabram P., Li W., Giroux D., Aguilar-Cordova E. Sensitivity and reproducibility in adenoviral infectious titer determination. Nat Med 1997, 3:808-811.
10. Banchereau J., Steinman R.M. Dendritic cells and the control of immunity. Nature 1998, 392:2445-2452.
11. Steinman R.M., Dhodapkar M. Active immunization against cancer with dendritic cells: the near future. Int J Cancer 2001, 94:459-473.
12. Morelli A.E., Larregina A.T., Ganster R.W., Zahorchak A.F., Plowey J.M., Takayama T., et al. Recombinant adenovirus induces maturation of dendritic cells via an NF-kappa B-dependent pathway. J Virol 2000, 74:9617-9628.
13. Mizukoshi E., Nakamoto Y., Marukawa Y., Arai K., Yamashita T., Tsuji H., et al. Cytotoxic T cell responses to human telomerase reverse transcriptase in patients with hepatocellular carcinoma. Hepatology 2006, 43:1284-1294.
14. Diebold S.S., Cotten M., Koch N., Zenke M. MHC class II presentation of endogenously expressed antigens by transfected dendritic cells. Gene Ther 2001, 8:487-493.
15. Kaplan J.M., Yu Q., Piraino S.T., Pennington S.E., Shankara S., Woodworth L.A., et al. Induction of antitumor immunity with dendritic cells transduced with adenovirus vector-encoding endogenous tumor-associated antigens. J Immunol 1999, 163:699-707.
16. Oh S.T., Kim C.H., Park M.Y., Won E.H., Sohn H.J., Cho H.I., et al. Dendritic cells transduced with recombinant adenoviruses induce more efficient anti-tumor immunity than dendritic cells pulsed with peptide. Vaccine 2006, 24:2860-2868.
17. Dupont J., Latouche J.B., Ma C., Sadelain M. Artificial antigen presenting cells transduced with telomerase efficiently expand epitope-specific, human leukocyte antigen-restricted cytotoxic T cells. Cancer Res 2005, 65:5417-5427.
18. Adotévi O., Mollier K., Neuveut C., Cardinaud S., Boulanger E., Mignen B., et al. Immunogenic HLA-B0702-restricted epitopes derived from human telomerase reverse transcriptase that elicit antitumor cytotoxic T-cell responses. Clin Cancer Res 2006, 12:3158-3167.
19. Zhou Q., Guo A.L., Xu C.R., An S.J., Wang Z., Yang S.Q., et al. A dendritic cell-based tumour vaccine for lung cancer: full-length XAGE-1b protein-pulsed dendritic cells induce specific cytotoxic T lymphocytes in vitro. Clin Exp Immunol 2008, 153:392-400.
20. Kirk C.J., Mulé J.J. Gene-modified dendritic cells for use in tumor vaccines. Hum Gene Ther 2000, 11:797-806.
21. Klein C., Bueler H., Mulligan R.C. Comparative analysis of genetically modified dendritic cells and tumor cells as therapeutic cancer vaccines. J Exp Med 2000, 191:1699-1708.
22. Kim S., Lee J.B., Lee G.K., Chang J. Vaccination with recombinant adenoviruses and dendritic cells expressing prostate-specific antigens is effective in eliciting CTL and suppresses tumor growth in the experimental prostate cancer. The Prostate 2009, 69:938-948.
23. Song W., Kong H.L., Carpenter H., Torii H., Granstein R., Rafii S., et al. Dendritic cells genetically modified with an adenovirus vector encoding the cDNA for a model antigen induce protective and therapeutic antitumor immunity. J Exp Med 1997, 186:1247-1256.
24. Ribas A., Butterfield L.H., Hu B., Dissette V.B., Chen A.Y., Koh A., et al. Generation of T-cell immunity to a murine melanoma using MART-1-engineered dendritic cells. J Immunother 2000, 23:59-66.
25. Cho H.I., Kim H.J., Oh S.T., Kim T.G. In vitro induction of carcinoembryonic antigen (CEA)-specific cytotoxic T lymphocytes by dendritic cells transduced with recombinant adenoviruses. Vaccine 2003, 22:224-236.
26. Rea D., Schagen F.H., Hoeben R.C., Mehtali M., Havenga M.J., Toes R.E., et al. Adenoviruses activate human dendritic cells without polarization toward a T-helper type 1-inducing subset. J Virol 1999, 73:10245-10253.
27. Jonuleit H., Tüting T., Steitz J., Brück J., Giesecke A., Steinbrink K., et al. Efficient transduction of mature CD83+ dendritic cells using recombinant adenovirus suppressed T-cell stimulatory capacity. Gene Ther 2000, 7:249-254.
28. Miller G., Lahrs S., Shah A.B., DeMatteo R.P. Optimization of dendritic cell maturation and gene transfer by recombinant adenovirus. Cancer Immunol Immunother 2003, 52:347-358.
29. Yang Y., Li Q., Ertl H.C., Wilson J.M. Cellular and humoral immune responses to viral antigens create barriers to lung-directed gene therapy with recombinant adenoviruses. J Virol 1995, 69:2004-2015.
30. Vucic D., Stennicke H.R., Pisabarro M.T., Salvesen G.S., Dixit V.M. ML-IAP, a novel inhibitor of apoptosis that is preferentially expressed in human melanomas. Curr Biol 2000, 10:1359-1366.
31. Trieb K., Lehner R., Stulnig T., Sulzbacher I., Shroyer K.R. Survivin expression in human osteosarcoma is a marker for survival. Eur J Surg Oncol 2003, 29:379-382.
32. Ashhab Y., Alian A., Polliack A., Panet A., Ben Yehuda D. Two splicing variants of a new inhibitor of apoptosis gene with different biological properties and tissue distribution pattern. FEBS Lett 2001, 495:56-60.
33. Gazzaniga P., Gradilone A., Giuliani L., Gandini O., Silvestri I., Nofroni I., et al. Expression and prognostic significance of LIVIN, SURVIVIN and other apoptosis related genes in the progression of superficial bladder cancer. Ann Oncol 2003, 14:85-90.
34. Xiang Y., Yao H., Wang S., Hong M., He J., Cao S., et al. Prognostic value of Survivin and Livin in nasopharyngeal carcinoma. Laryngoscope 2006, 116:126-130.
35. Yuan D., Liu L., Xu H., Gu D. The effects on cell growth and chemosensitivity by livin RNAi in non-small cell lung cancer. Mol Cell Biochem 2009, 320:133-140.
36. Hariu H., Hirohashi Y., Torigoe T., Asanuma H., Hariu M., Tamura Y., et al. Aberrant expression and potency as a cancer immunotherapy target of inhibitor of apoptosis protein family, Livin/ML-IAP in lung cancer. Clin Cancer Res 2005, 11:1000-1009.
37. Steitz J., Brück J., Steinbrink K., Enk A., Knop J., Tüting T. Genetic immunization of mice with human tyrosinaserelated protein 2: implications for the immunotherapy of melanoma. Int J Cancer 2000, 86:89-94.
38. Ciesielski M.J., Apfel L., Barone T.A., Castro C.A., Weiss T.C., Fenstermaker R.A. Antitumor effects of a xenogeneic survivin bone marrow derived dendritic cell vaccine against murine GL261 gliomas. Cancer Immunol Immunother 2006, 55:1491-1503.
39. Fenstermaker R.A., Ciesielski M.J. Immunotherapeutic strategies for malignant gliomas. Cancer Control 2004, 11:181-191.